In our study, increased miR-155 and decreased SOCS1 expressions in splenic CD8+ T cells are much agreement with the aforementioned investigations, which demonstrated that co-treatment OMT with DDP can enhanced antitumor immunity via miR-155-SOCS1 signaling pathway in mice bearing LLC tumor. This evidence concerns the gene SOCS1 and neoplasm.